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SY2 HOW DOES DENOSUMAB CONTRIBUTE TO THE UNMET NEEDS IN FRACTURE REDUCTION? S. Papapoulos Leiden University Medical Center, Department of Endocrinology & Metabolic Diseases, Leiden, Netherlands
Denosumab inhibits the development, activity and survival of osteoclasts, increases bone mineral density (BMD) and reduces the risk of fracture. 1 BMD increases continuously for up to 8 years, as shown at the lumbar spine and total hip over 3, 1 6 2 and 8 years. 3 The pivotal FREEDOM trial demonstrated that denosumab reduced the risk of new vertebral, nonvertebral and hip fractures at 3 years. 1 However, osteoporosis is a chronic condition, and most women will need protection for more than 3 years. In an open-label extension of the FREEDOM trial, new vertebral and nonvertebral fracture incidence remained low in patients who had received denosumab for 6 years. 2 Pre-specified analysis of the FREEDOM data showed that denosumab reduced the incidence of new vertebral fractures irrespective of age (< vs ≥75 years), prior nonvertebral fracture, prevalent vertebral fracture, or femoral neck BMD T-score (> vs ≤-2.5).
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The FREEDOM trial included patients at lower risk of fracture, as demonstrated by the low incidence of new vertebral and nonvertebral fractures in the placebo group. 5 Post hoc analysis of women at higher risk of fracture (multiple and/or moderate or severe prevalent vertebral fractures; age ≥75 years; femoral neck BMD T-score ≤-2.5) in FREEDOM demonstrated that denosumab reduced the incidence of new vertebral and hip fractures in these subgroups of patients. Denosumab has been shown to significantly reduce the fracture risk at hip, spine and nonvertebral sites. Moreover, in the pivotal FREEDOM trial, there were no significant differences in the total incidence of adverse events (AEs), serious AEs (SAEs) or discontinuation of study treatment because of AEs between the denosumab (N03886) and placebo groups (N03876). In addition, no significant differences were observed in the overall incidence of cancer, cardiovascular events, or either AEs or SAEs of infection. 1 However, a significant difference in AEs of eczema (p< 0.001) and SAEs of cellulitis (p00.002) was observed between denosumab and placebo. Watts et al compared the incidence of AEs and SAEs in the FREEDOM study, categorized as "Infections and Infestations" in the MedDRA system organ class, between the placebo and denosumab arms, exploring the temporal relationship between occurrence of SAEs of infections of interest and administration of denosumab. 2 Although there was a numerical difference in SAEs of infection involving the gastrointestinal system, renal and urinary system, ear, and endocarditis when denosumab and placebo were compared, the number of events was small and no relationship was found between SAEs of infection and timing of administration or duration of exposure to denosumab. Detailed analysis of year-to-year observed subject incidence rates of SAEs of infection and AEs of malignancy in the FREEDOM trial and its 2-year extension study (denosumab/denosumab or placebo/denosumab) showed that rates in the first 2 years of the extension for both groups were similar to those observed in the FREE-DOM placebo group. 3 This was also shown for individual SAEs of infection, including cellulitis or erysipelas, and individual malignancies. Osteonecrosis of the jaw was not recorded in FREEDOM and was infrequent in the first 2 years of the extension study; cases have generally resolved with appropriate management. References: Glucosamine is an amino-monosaccharide and a natural constituent of glycosaminoglycans in articular cartilage. When administered exogenously, it is used for the treatment of osteoarthritis as a prescription drug or a dietary supplement. The latter use is mainly supported by its perception as a cartilage building block, but it actually exerts specific pharmacological effects, mainly decreasing interleukin 1-induced gene expression by inhibiting the cytokine intracellular signalling cascade in general and NFκB activation in particular. The product is also effective in animal models of osteoarthritis and has a sound biological plausibility. As a whole, the use of glucosamine in the management of osteoarthritis is supported by the clinical trials performed with the original prescription product, i.e. crystalline glucosamine sulfate. This is the stabilized form of glucosamine sulfate, while other formulations or different glucosamine salts (e.g., hydrochloride) have never been shown effective. In particular, long-term pivotal trials of crystalline glucosamine sulfate 1500 mg once daily have shown significant and clinically relevant improvement of pain and function limitation (symptom-modifying effect) in knee osteoarthritis. Continuous administration for up to 3 years resulted in significant reduction in the progression of joint structure changes compared with placebo as assessed by measuring radiological joint space narrowing (structure-modifying effect). The two effects combined may suggest a diseasemodifying effect, that was postulated based on an observed decrease in the risk of undergoing total joint replacement in the follow-up of patients receiving the product for at least 12 months in the pivotal trials. Compared with other glucosamine formulations, salts or dosage forms, the prescription product achieves higher plasma and synovial fluid concentrations that are above the threshold for a pharmacologically relevant effect and may therefore justify its distinct therapeutic characteristics. Crystalline glucosamine sulfate 1500 mg once daily is therefore recommended in the majority of clinical practice guidelines and was found costeffective in pharmacoeconomic analyses, despite contradictory findings in few recent meta-analyses, biased by many methodological errors compared with those with a favourable assessment. The safety of the drug is good in clinical trials and in the post-marketing surveillance.
SY17 STATE OF THE ART LECTURE: VISCOSUPPLE-MENTATION WITH HYALURONIC ACID IN OSTEOARTHRITIS E. Maheu
Rheumatology department, AP-HP, Saint-Antoine Hospital, Paris, France Hyaluronic acid preparations are currently part of daily knee osteoarthritis (KOA) treatment, cited in all international recommendations for the management of KOA. Nevertheless its efficacy remains debated, and meta-analyses, although most of them advocate for HA efficacy, remain controversial. Some recent data published in literature can be added to this ongoing discussion. Besides, it has been stated in numerous previous papers that HA efficacy could depend upon a high molecular weight (MW), which currently seems to be contradicted by new facts. A recent multicentre randomized controlled trial compared Hyalgan versus placebo in 337 KOA patients followed up to 1 year failed to identify a superiority of the HA on the primary outcome which was the "time to recurrence", i.e. the time between the onset of improvement of the Lequesne index and the time when it deteriorates. A randomized, placebocontrolled trial performed with 4 repetitions of cycles of 5 injections with Adant at baseline, 6 month, 1 and 2 years followed the patients up to 40 months, showing a sustained superiority of the HA over placebo from the 14 month assessment until the endpoint. A recent metaanalysis looked at the "therapeutic trajectory following IA HA injections" in KOA, analysing 54 trials Of interest, in all these trials, HA preparations were equally safe and well tolerated, with no major safety concern, especially in terms of acute postinjection pseudoseptic arthritis.
Conclusion: Recent publications on HA treatment in knee OA add data showing its efficacy. There seem to be a medium-to long-term sustained effect, which may be pursued but the repetition of cycles of treatment. There is no superior efficacy related to the MW. One HA preparation (GO-ON) showed not only non-inferiority, but also superiority over the control HA product.
reported in 49 articles, and calculated the effect size for pain on a VAS by time intervals. A modest, but sustained effect was observed from week 4 until week 24, culminating at week 8, then decreasing slightly. Several trials comparing various HA preparations according to a multicentre, randomized, controlled, double-blind, noninferiority design have recently been performed and reported (Table below) : they were all high quality trial despite some disparities, and all concluded to noninferiority between the tested HA products, regardless of the MW. One trial could not only conclude to noninferiority, but also to a statistically significant superiority of the test HA GO-ON versus Hyalgan in the full analysis set population (p00.021). This statistical superiority translated into a clinically relevant difference in terms of OMERACT-OARSI responders rate: 82% with GO-ON vs 67% with Hyalgan (p00.0007). The round-table will address the importance of nutrition in osteoporosis prevention and the relationship between a food-related health condition and its potential impact on healthcare expenditures. The speakers will specifically answer 3 sets of questions: How much and when? How and how to improve adherence? Cost vs benefit: is it worth it? They will review and comment the evidence about optimized intakes of calcium & vitamin D for the maintenance of bone health and the reduction of the risk of developing osteoporosis. They will then highlight the existing gap between nutritional intakes and recommended amounts of key bone nutrients, discuss the difficulty encountered by women over 50 years of age to achieve those and propose solutions that can be considered to improve adherence. Recent data about the health economic impact of foods and more particularly dairy products on the burden of osteoporosis in the general population over 50 years of age will also be shared and discussed.
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